Treatment of early stage chronic hepatitis C virus infection

References

• Ponziani FR, Mangiola F, Binda C, et al. Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. World J Hepatol. 2017 Mar 8;9(7):352–367.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Gasbarrini A, Pompili M, et al. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. Transplant Proc. 2011 Jan-Feb;43(1):291–295.
   PubMed Web of Science ®Google Scholar
• Global report on access to hepatitis C treatment. Focus on overcoming barriers. World Health Organization. 2016.
   Google Scholar
• Peltekian KM. Blue-print for elimination of hepatitis C virus infection: one step closer. Ann Hepatol. 2017 Sep-Oct;16(5):696–698.
   PubMedGoogle Scholar
• Fox DS, McCombs JS. Optimizing HCV treatment – moving beyond the cost conundrum. J Hepatol. 2016 Jul;65(1):222–225.
   PubMed Web of Science ®Google Scholar
• Marcellin F, Roux P, Protopopescu C, et al. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):259–268.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Petta S, Craxì A. Is global elimination of HCV realistic? Liver Int. 2018 Feb;38(Suppl 1):40–46.
   PubMedGoogle Scholar
• Sagnelli E, Alessio L, Sagnelli C, et al. Clinical findings of HCV chronic infection in undocumented immigrants and low-income refugees in three areas of Southern Italy. Ann Hepatol. 2018 Jan-Feb;17(1):47–53.
   PubMedGoogle Scholar
• Daw MA, El-Bouzedi A, Ahmed MO, et al. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa. Travel Med Infect Dis. 2016 Sep-Oct;14(5):517–526.
   PubMed Web of Science ®Google Scholar
• Greenaway C, Thu Ma A, Kloda LA, et al. The seroprevalence of hepatitis C antibodies in immigrants and refugees from intermediate and high endemic countries: a systematic review and meta-analysis. PLoS One. 2015 Nov;10(11):e0141715.
   PubMed Web of Science ®Google Scholar
• Boglione L, Cusato J, Cariti G, et al. Role of IL28B genotype in the liver stiffness increase in untreated patients with chronic hepatitis C. Infect Genet Evol. 2017;53:195–198.
   PubMed Web of Science ®Google Scholar
• Heim MH, Bochud PY, George J. Host – hepatitis C viral interactions: the role of genetics. J Hepatol. 2016 Oct;65(1 Suppl):S22–S32.
   PubMedGoogle Scholar
• Jezequel C, Bardou-Jacquet E, Desille Y, et al. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 years follow-up. J Hepatol. 2015;62(Suppl.2):S589.
   Google Scholar
• Younossi ZM, Henry L, Park H, et al. Depression and chronic hepatitis C (CH-C): a common and costly association. Am J Gastroenterol. 2015;110(Suppl.1s):S874–S875.
   Google Scholar
• Henry L, Whitley K, Dhakal K, et al. A systematic review assessing the impact of chronic hepatitis C on health-related quality of life and patient-reported outcomes. Am J Gastroenterol. 2014 Dec 15;109(Suppl.2s):S178.
   PubMedGoogle Scholar
• Younossi ZM, Birerdinc A, Henry L. Hepatitis C infection: a multi-faceted systemic disease with clinical, patient reported and economic consequences. J Hepatol. 2016 Oct;65(1 Suppl):S109–S119.
   PubMedGoogle Scholar
• Spiegel BM, Younossi ZM, Hays RD, et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Bieliauskas L, Back-Madruga C, et al. Cognitive function in hepatitis C patients with advanced brosis enrolled in the HALT-C trial. J Hepatol. 2005;43:614–622.
   PubMed Web of Science ®Google Scholar
• Yarlott L, Heald E, Forton D. Hepatitis C virus infection, and neurological and psychiatric disorders – a review. J Adv Res. 2017 Mar;8:139–148.
   PubMed Web of Science ®Google Scholar
• Alsop D, Younossi Z, Stepanova M, et al. Cerebral MR spectroscopy and patient-reported mental health outcomes in hepatitis C genotype 1 naive patients treated with ledipasvir and sofosbuvir. Hepatology. 2014;60:221A.
   Google Scholar
• Loria A, Doyle K, Weinstein AA, et al. Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil. 2014 Apr;93(6):470–476.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Gragnani L, Comarmond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014 Dec 15;46(Suppl.5):S165–S173.
   PubMedGoogle Scholar
• Cacoub P, Comarmond C, Domont F, et al. Cryoglobulinemia vasculitis. Am J Med. 2015 Sep;128(9):950–955.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016 Feb;3(1):3–14.
   PubMed Web of Science ®Google Scholar
• Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011 Jun;63(6):1748–1757.
   PubMedGoogle Scholar
• Saadoun D, Delluc A, Piette JC, et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol. 2008 Jan;20(1):23–28.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Fognani E, Piluso A, et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015 Apr;61(4):1145–1153.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153–194.
   PubMedGoogle Scholar
• Saadoun D, Thibault V, Si Ahmed SN, et al. Sofosbuvir plus ribavirin for hepatitis C virus associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2016 Oct;75(10):1777–1782.
   PubMed Web of Science ®Google Scholar
• Gragnani L, Piluso A, Urraro T, et al. Virological and clinical response to interferon-free regimens in patients with HCV-related mixed cryoglobulinemia: preliminary results of a prospective pilot study. Curr Drug Targets. 2017;18(7):772–785.
   PubMed Web of Science ®Google Scholar
• Sise ME, Bloom AK, Wisocky J, et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016 Feb;63(2):408–417.
   PubMed Web of Science ®Google Scholar
• Bonacci M, Lens S, Londono MC, et al. Virologic, clinical, and immune response outcomes of patients with hepatitis C virus-associated cryoglobulinemia treated with direct-acting antivirals. Clin Gastroenterol Hepatol. 2017 Apr;15(4):575–583.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Hampel H, Yeh C, et al. Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 2002 Dec;36(6):1439–1445.
   PubMed Web of Science ®Google Scholar
• Nuño Solinís R, Arratibel Ugarte P, Rojo A, et al. Value of treating all stages of chronic hepatitis C: a comprehensive review of clinical and economic evidence. Infect Dis Ther. 2016 Dec;5(4):491–508.
   PubMed Web of Science ®Google Scholar
• Dalrymple LS, Koepsell T, Sampson J, et al. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol. 2007 Jul;2(4):715–721.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Plaisier E, Saadoun D, et al. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Am J Kidney Dis. 2013 Apr;61(4):623–637.
   PubMed Web of Science ®Google Scholar
• Butt AA, Wang X, Fried LF. HCV infection and the incidence of CKD. Am J Kidney Dis. 2011 Mar;57(3):396–402.
   PubMed Web of Science ®Google Scholar
• Huang J-F, Chuang W-L, Dai C-Y, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med. 2006 Sep;260(3):255–262.
   PubMed Web of Science ®Google Scholar
• Lee -J-J, Lin M-Y, Yang Y-H, et al. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis. 2010 Jul;56(1):23–31.
   PubMed Web of Science ®Google Scholar
• Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int. 2005 Jan;67(1):285–290.
   PubMed Web of Science ®Google Scholar
• Wyatt CM, Malvestutto C, Coca SG, et al. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. Aids. 2008 Sep;22(14):1799–1807.
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012 Aug;206(4):469–477.
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Caracciolo F, et al. Non-Hodgkin’s lymphoma: possible role of hepatitis C virus. Jama. 1994 Aug 3;272(5):355–356.
   PubMed Web of Science ®Google Scholar
• Ferri C, Lo Jacono F, Monti M, et al. Lymphotropic virus infection of peripheral blood mononuclear cells in B-cell non-Hodgkin’s lymphoma. Acta Haematol. 1997;98(2):89–94.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Garcıa-Buey L, Pajares JM, et al. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology. 2003 Dec;125(6):1723–1732.
   PubMed Web of Science ®Google Scholar
• dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomark Prev. 2006 Nov;15(11):2078–2085.
   PubMed Web of Science ®Google Scholar
• Matsuo K, Kusano A, Sugumar A, et al. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004 Sep;95(9):745–752.
   PubMed Web of Science ®Google Scholar
• Negri E, Little D, Boiocchi M, et al. B-cell non-Hodgkin’s lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer. 2004 Aug 10;111(1):1–8.
   PubMed Web of Science ®Google Scholar
• De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol. 2008 Apr;6(4):451–458.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Nakayama C, Kamada K, et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol. 2017 Dec;96(12):2057–2061.
   PubMed Web of Science ®Google Scholar
• Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin’s lymphoma. Hepatology. 2018 Jan;67(1):48–55.
   PubMed Web of Science ®Google Scholar
• Olubamwo OO, Onyeka IN, Miettola J, et al. Hepatitis C as a risk factor for carotid atherosclerosis – a systematic review. Clin Physiol Funct Imaging. 2016 Jul;36(4):249–260.
   PubMed Web of Science ®Google Scholar
• He H, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PloS One. 2013 Nov 12;8(11):e81305.
   PubMed Web of Science ®Google Scholar
• Liao CC, Su TC, Sung FC, et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PloS One. 2012;7(2):e31527.
   PubMed Web of Science ®Google Scholar
• Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis. 2009 Jul 15;49(2):225–232.
   PubMed Web of Science ®Google Scholar
• Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016 May;36(5):621–627.
   PubMed Web of Science ®Google Scholar
• White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008 Nov;49(5):831–844.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Nader F, et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013 Mar;37(6):647–652.
   PubMed Web of Science ®Google Scholar
• Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol. 2008 Mar 15;167(6):743–750.
   PubMed Web of Science ®Google Scholar
• Liao CC, Su TC, Sung FC, et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One. 2012;7:e31527.
   PubMed Web of Science ®Google Scholar
• Pavone P, Tieghi T, d’Ettorre G, et al. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016 May;22(5):462.e1–3.
   PubMed Web of Science ®Google Scholar
• Adinolfi LE, Nevola R, Guerrera B, et al. HCV clearance by direct-acting antiviral treatments reverses insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2017 Dec 11. DOI:10.1111/jgh.14067
   PubMedGoogle Scholar
• Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018 Feb;90(2):320–327.
   PubMed Web of Science ®Google Scholar
• Petta S. Hepatitis C virus and cardiovascular: a review. J Adv Res. 2017 Mar;8(2):161–168.
   PubMed Web of Science ®Google Scholar
• Soriano V, Barreiro P, de Mendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. 2016;63:2065–2066.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, −2, and −3 clinical trials. Hepatology. 2015 Jun;61(6):1798–1808.
   Google Scholar
• Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016 Jul;65(1):33–39.
   PubMed Web of Science ®Google Scholar
• Gerber L, Estep M, Stepanova M, et al. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2016 Jan;14(1):156–164.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Asselah T, et al. Hepatitis C in patients with minimal or no hepatic fibrosis: the impact of treatment and sustained virologic response on patient-reported outcomes. Clin Infect Dis. 2017 Dec 20. DOI:10.1093/cid/cix1106
   PubMedGoogle Scholar
• Hughes BL, Page CM, Kuller JA. Hepatitis C in pregnancy: screening, treatment, and management. Am J Obstet Gynecol. 2017 Nov;217(5):B2–B12.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, Siciliano M, Lionetti R, et al. Effectiveness of paritaprevir/ritonavir/ombitasvir/dasabuvir in hemodialysis patients with hepatitis C virus infection and advanced liver fibrosis: case reports. Am J Kidney Dis. 2017 Aug;70(2):297–300.
   Google Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015 Oct 17;386(10003):1537–1545.
   PubMed Web of Science ®Google Scholar
• Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016 Jun;150(7):1590–1598.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012 Sep;19(9):601–607.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Donato FM, Messa P. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.). Int J Artif Organs. 2017 Oct 13;40(10):531–541.
   PubMed Web of Science ®Google Scholar
• Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011 Aug 13;378(9791):571–583.
   PubMed Web of Science ®Google Scholar
• Soriano V, Young B, Reau N. Report from the international conference on viral hepatitis - 2017. AIDS Rev. 2018 Jan 25;20(1).
   PubMedGoogle Scholar
• Shiffmann ML. The next wave of hepatitis C virus: the epidemic of intravenous drug use. Liver International. 2018;38(Suppl. 1):34–39.
   PubMedGoogle Scholar
• Chahal HS, Marseille EA, Tice JA, et al. Cost-effectiveness of early treatment of hepatitis c virus genotype 1 by stage of liver fibrosis in a us treatment-naive population. JAMA Intern Med. 2016 Jan;176(1):65–73.
   PubMed Web of Science ®Google Scholar
• McEwan P, Selvapatt N, Brown A, et al. A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. Eur J Gastroenterol Hepatol. 2017 Feb;29(2):208–214.
   PubMed Web of Science ®Google Scholar
• Chen H, Chen L. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China. PLoS ONE. 2017 Apr 5;12(4):e0175189.
   PubMed Web of Science ®Google Scholar
• Ethgen O, Sanchez Gonzalez Y, Jeanblanc G, et al. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population. J Med Econ. 2017 Feb;20(2):162–170.
   PubMed Web of Science ®Google Scholar
• Pascual-Argente N, Puig-Junoy J, Llagostera-Punzano A. Non-healthcare costs of hepatitis C: a systematic review. Expert Rev Gastroenterol Hepatol. 2018 Jan;12(1):19–30.
   PubMed Web of Science ®Google Scholar
• Sievert W, Razavi H, Estes C, et al. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia. J Gastroenterol Hepatol. 2014 Aug;29(Suppl 1):1–9.
   PubMedGoogle Scholar
• Deuffic-Burban S, Mathurin P, Rosa I, et al. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. Dig Liver Dis. 2014 Feb;46(2):157–163.
   PubMedGoogle Scholar
• Chan HLY, Chen CJ, Omede O, et al. The present and future disease burden of hepatitis C virus infections with today’s treatment paradigm: volume 4. J Viral Hepat. 2017 Oct;24(Suppl 2):25–43.
   PubMedGoogle Scholar
• Willemse SB, Razavi-Shearer D, Zuure FR, et al. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms. Neth J Med. 2015 Nov;73(9):417–431.
   PubMed Web of Science ®Google Scholar
• MüLlhaupt B, Bruggmann P, Bihl F, et al. Modeling the health and economic burden of hepatitis C virus in Switzerland. PLoS ONE. 2015;10(6):e0125214.
   PubMed Web of Science ®Google Scholar
• Duberg AS, Blach S, Falconer K, et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015 Feb;50(2):233–244.
   PubMed Web of Science ®Google Scholar
• Kabiri M, Jazwinski AB, Roberts MS, et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 2014 Aug 5;161(3):170–180.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Horsmans Y. Towards eradication of hepatitis C virus from dialysis units. Lancet. 2015 Oct;386(10003):1514–1515.
   PubMed Web of Science ®Google Scholar
• Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018 Mar;68(3):402–411.
   PubMed Web of Science ®Google Scholar
• Zelenev A, Li J, Mazhnaya A, et al. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis. 2018 Feb;18(2):215–224.
   PubMed Web of Science ®Google Scholar
• van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama. 2012 Dec;308(24):2584–2593.
   PubMed Web of Science ®Google Scholar
• Welsch C, Efinger M, von Wagner M, et al. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response. PLoS One. 2017;12:e0171755.
   PubMed Web of Science ®Google Scholar